Given the localization of A2A and NR2B receptors within the basal ganglia and the numerous lines of evidence which suggest that they interact on a molecular level, we wanted to test if NR2B and A2A antagonist combination treatment might indeed provide increased efficacy in PD models. Here, GRIN2B is linked to Parkinson disease.